Babulal, Ganesh M. Ghoshal, Nupur Head, Denise Vernon, Elizabeth K. Holtzman, David M. Benzinger, Tammie L.S. Fagan, Anne M. Morris, John C. and Roe, Catherine M. 2016. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. The American Journal of Geriatric Psychiatry,
Breitve, Monica H. Hynninen, Minna J. Brønnick, Kolbjørn Chwiszczuk, Luiza J. Auestad, Bjørn H. Aarsland, Dag and Rongve, Arvid 2016. A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease. Alzheimer's Research & Therapy, Vol. 8, Issue. 1,
Brown, Eric E. Iwata, Yusuke Chung, Jun Ku Gerretsen, Philip Graff-Guerrero, Ariel and Motoi, Yumiko 2016. Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, p. 1.
Fung, Ada Wai Tung and Lam, Linda Chiu Wa 2016. A cross-sectional study on clinical correlates of anxiety disorders in 613 community living older adults in Hong Kong. International Journal of Geriatric Psychiatry,
Huang, Huang Nie, Sipei Cao, Min Marshall, Charles Gao, Junying Xiao, Na Hu, Gang and Xiao, Ming 2016. Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice. AGE,
Mah, Linda Szabuniewicz, Claudia and Fiocco, Alexandra J. 2016. Can anxiety damage the brain?. Current Opinion in Psychiatry, Vol. 29, Issue. 1, p. 56.
Perna, Giampaolo Iannone, Giuseppe Alciati, Alessandra and Caldirola, Daniela 2016. Are Anxiety Disorders Associated with Accelerated Aging? A Focus on Neuroprogression. Neural Plasticity, Vol. 2016, p. 1.
Bensamoun, David Guignard, Renaud Furst, Ansgar J. Derreumaux, Alexandre Manera, Valeria Darcourt, Jacques Benoit, Michel Robert, Philippe H. and David, Renaud 2015. Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People. Journal of Alzheimer's Disease, Vol. 49, Issue. 2, p. 387.
Cummings, Damian M. Liu, Wenfei Portelius, Erik Bayram, Sevinç Yasvoina, Marina Ho, Sui-Hin Smits, Hélène Ali, Shabinah S. Steinberg, Rivka Pegasiou, Chrysia-Maria James, Owain T. Matarin, Mar Richardson, Jill C. Zetterberg, Henrik Blennow, Kaj Hardy, John A. Salih, Dervis A. and Edwards, Frances A. 2015. First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression. Brain, Vol. 138, Issue. 7, p. 1992.
Lin, Qiao Cao, Yunpeng and Gao, Jie 2015. The impacts of a GO-game (Chinese chess) intervention on Alzheimer disease in a Northeast Chinese population. Frontiers in Aging Neuroscience, Vol. 7,
Liu, Celina S. Chau, Sarah A. Ruthirakuhan, Myuri Lanctôt, Krista L. and Herrmann, Nathan 2015. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease. CNS Drugs, Vol. 29, Issue. 8, p. 615.
Mah, Linda Binns, Malcolm A. and Steffens, David C. 2015. Anxiety Symptoms in Amnestic Mild Cognitive Impairment Are Associated with Medial Temporal Atrophy and Predict Conversion to Alzheimer Disease. The American Journal of Geriatric Psychiatry, Vol. 23, Issue. 5, p. 466.
Tifratene, Karim Robert, Philippe Metelkina, Asya Pradier, Christian and Dartigues, Jean François 2015. Progression of mild cognitive impairment to dementia due to AD in clinical settings. Neurology, Vol. 85, Issue. 4, p. 331.
Weiner, Michael W. Veitch, Dallas P. Aisen, Paul S. Beckett, Laurel A. Cairns, Nigel J. Cedarbaum, Jesse Green, Robert C. Harvey, Danielle Jack, Clifford R. Jagust, William Luthman, Johan Morris, John C. Petersen, Ronald C. Saykin, Andrew J. Shaw, Leslie Shen, Li Schwarz, Adam Toga, Arthur W. and Trojanowski, John Q. 2015. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's & Dementia, Vol. 11, Issue. 6, p. e1.
Xing, Yi Tang, Yi and Jia, Jianping 2015. Sex Differences in Neuropsychiatric Symptoms of Alzheimer’s Disease: The Modifying Effect of Apolipoprotein Eε4 Status. Behavioural Neurology, Vol. 2015, p. 1.
You, S. Christine Walsh, Christine M. Chiodo, Louis A. Ketelle, Robin Miller, Bruce L. and Kramer, Joel H. 2015. Neuropsychiatric Symptoms Predict Functional Status in Alzheimer’s Disease. Journal of Alzheimer's Disease, Vol. 48, Issue. 3, p. 863.
de Bruijn, Renée F.A.G. Direk, Nese Mirza, Saira Saeed Hofman, Albert Koudstaal, Peter J. Tiemeier, Henning and Ikram, M. Arfan 2014. Anxiety Is Not Associated with the Risk of Dementia or Cognitive Decline: The Rotterdam Study. The American Journal of Geriatric Psychiatry, Vol. 22, Issue. 12, p. 1382.
Gavrilova, S. I. Preuss, U. W. Wong, J. W. M. Hoerr, R. Kaschel, R. and Bachinskaya, N. 2014. Efficacy and safety ofGinkgo bilobaextract EGb 761®in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. International Journal of Geriatric Psychiatry, Vol. 29, Issue. 10, p. 1087.
Pietrzak, R. H. Scott, J. C. Neumeister, A. Lim, Y. Y. Ames, D. Ellis, K. A. Harrington, K. Lautenschlager, N. T. Szoeke, C. Martins, R. N. Masters, C. L. Villemagne, V. L. Rowe, C. C. and Maruff, P. 2014. Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. The British Journal of Psychiatry, Vol. 204, Issue. 5, p. 400.
Anxiety, apathy and depression are common in subjects with mild cognitive impairment (MCI) and may herald Alzheimer's disease (AD). We investigated whether these symptoms correlated with cerebrospinal fluid (CSF) markers for AD in subjects with MCI.
Subjects with MCI (n=268) were selected from the ‘Development of screening guidelines and criteria for pre-dementia Alzheimer's disease’ (DESCRIPA) and Alzheimer's Disease Neuroimaging Initiative (ADNI) studies. We measured amyloid β(1-42) protein (Aβ42) and total tau (t-tau) in CSF. Neuropsychiatric symptoms were measured with the Neuropsychiatric Inventory.
Depressive symptoms were reported by 55 subjects (21%), anxiety by 35 subjects (13%) and apathy by 49 subjects (18%). The presence of anxiety was associated with abnormal CSF Aβ42 [odds ratio (OR) 2.3, 95% confidence interval (CI) 1.6–3.3] and t-tau (OR 2.6, 95% CI 1.9–3.6) concentrations and with the combination of abnormal concentrations of both Aβ42 and t-tau (OR 3.1, 95% CI 2.0–4.7). The presence of agitation and irritability was associated with abnormal concentrations of Aβ42 (agitation: OR 1.6, 95% CI 1.1–2.3; irritability: OR 2.2, 95% CI 1.5–3.3). Symptoms of depression and apathy were not related to any of the CSF markers.
In subjects with MCI, symptoms of anxiety, agitation and irritability may reflect underlying AD pathology, whereas symptoms of depression and apathy do not.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.